Last reviewed · How we verify
metformin + glimepiride
This combination reduces blood glucose by increasing insulin secretion and improving insulin sensitivity in type 2 diabetes patients.
This combination reduces blood glucose by increasing insulin secretion and improving insulin sensitivity in type 2 diabetes patients. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | metformin + glimepiride |
|---|---|
| Also known as | rosiglitazone-metformin fixed dose combination |
| Sponsor | GlaxoSmithKline |
| Drug class | Antidiabetic combination (biguanide + sulfonylurea) |
| Target | Metformin: mitochondrial glycerophosphate dehydrogenase; Glimepiride: ATP-sensitive potassium channel (KATP) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity, while glimepiride stimulates pancreatic beta cells to increase insulin secretion. Together, they address both insulin resistance and beta-cell dysfunction in type 2 diabetes through complementary mechanisms.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)
- Headache
- Dizziness
- Weight gain
- Lactic acidosis (rare)
Key clinical trials
- Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients (PHASE4)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes (PHASE4)
- Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure (PHASE3)
- Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients (NA)
- A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria (PHASE4)
- Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults (PHASE1)
- Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metformin + glimepiride CI brief — competitive landscape report
- metformin + glimepiride updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI